Decades have passed since the first nanoparticles-base medicine was approved for human
cancer treatment, and the research and development of nanoparticles for drug delivery are …

Over the past decade, the therapeutic potential of nanomaterials as novel drug delivery
systems complementing conventional pharmacology has been widely acknowledged …

A remaining challenge in the treatment of glioblastoma multiforme (GBM) is surmounting the
blood–brain barrier (BBB). Such a challenge prevents the development of efficient …

RNAs are involved in the crucial processes of disease progression and have emerged as
powerful therapeutic targets and diagnostic biomarkers. However, efficient delivery of …

In recent decades, extracellular vesicles (EVs), as bioactive cell-secreted nanoparticles
which are involved in various physiological and pathological processes including cell …

Immunotherapy has delivered impressive outcomes in combating tumor malignancies.
However, insufficient immune infiltration and poor immunogenicity within the tumor …

Novel green technology RNA pesticide has been put forward as a promising method for
plant protection, but the instability and short life disadvantage of double-stranded RNA …

siRNA therapeutics have gained extensive attention, and to date six siRNAs are approved
for clinical use. Despite being investigated for the treatment of metabolic, cardiovascular …

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor
with a high mortality rate. Immunotherapy has achieved promising clinical results in multiple …

The interplay between the tumor cells and their microenvironments is as inseparable as the
relationship between “seeds” and “soil.” The tumor microenvironments (TMEs) exacerbate …